← back to search

Mingjun Zhang

Anhui Medical University · CN
Area of research
Oncology · Cancer Research
Research interest
Research interests include Medicine, Sorafenib, Bevacizumab, Hepatocellular carcinoma, Open label, and Trastuzumab.
h-index
—
citations
42
works
2
NIH funding
—
primary concept
—
email
✉ Find email ↗

Recent publications

Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial
˜The œLancet. Gastroenterology & hepatology 2025cited by 35position: middledoi
Disitamab vedotin (DV) plus toripalimab (Tor) and chemotherapy (C)/trastuzumab (Tra) as first-line (1L) treatment of patients (pts) with HER2-expressing locally advanced or metastatic (la/m) gastric cancer.
Journal of Clinical Oncology 2025cited by 7position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Dongyan Cai · Dalian Medical University1 papers (2025–2025)Meili Sun · Shandong University1 papers (2025–2025)Xiang Wang · Xuzhou Medical College1 papers (2025–2025)Feng Ye · Merck & Co., Inc., Rahway, NJ, USA (United States)1 papers (2025–2025)Lin Shen · Ministry of Education1 papers (2025–2025)Ting Deng · Tianjin Medical University1 papers (2025–2025)— · 1 papers (2025–2025)— · 1 papers (2025–2025)Yin Jin · Wenzhou Medical University1 papers (2025–2025)Yanqiao Zhang · Harbin Medical University1 papers (2025–2025)— · 1 papers (2025–2025)Jun Zhang · Qingdao University1 papers (2025–2025)Huiting Xu · Nantong University1 papers (2025–2025)Jianzhi Liu · Jiangsu University1 papers (2025–2025)Jianmin Fang · Tongji University1 papers (2025–2025)Hong Zong · First Affiliated Hospital of Zhengzhou University1 papers (2025–2025)Zhi Peng · Kunming University of Science and Technology1 papers (2025–2025)